{"id":780971,"date":"2023-08-30T10:20:26","date_gmt":"2023-08-30T14:20:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/"},"modified":"2023-08-30T10:20:26","modified_gmt":"2023-08-30T14:20:26","slug":"cognition-therapeutics-announces-participation-in-upcoming-september-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/","title":{"rendered":"Cognition Therapeutics Announces Participation in Upcoming September Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PURCHASE, N.Y., Aug.  30, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_FUQTVQ6ImJES9wEFmUY8Uo24WrK4nh3QV3PELNZKrd9me8em5m1ikIRrW5KHMms1AZPBPhZ2YKjcgIStonjRTrvx0MsoCwqVnXIOgzzPbo=\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Cognition Therapeutics, Inc.<\/strong><\/a><strong>\u00a0(Nasdaq: CGTX),\u00a0<\/strong>a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the \u201cCompany\u201d or \u201cCognition\u201d), announced that <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gGgpd26X_EzrhWWe4Mffj0Vc8CYFia35mk613cI--62J2q1pG0tMN3uOFfOtnX-4mv852k_N-4-q4abY99HNs4Vsz0mseeOC3E1Majs9Lhnl9JtN8AJneRulxgLtS9zL\" rel=\"nofollow noopener\" target=\"_blank\">Lisa Ricciardi<\/a>, Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright Annual Global Investment Conference and participating on a panel at the Cantor Fitzgerald Global Healthcare Conference in September 2023. In addition, she will be moderating a panel on pipeline prioritization strategies at the Longwood Healthcare Leaders Fall Conference, a brainstorming forum of pharmaceutical, healthcare and investment leaders focused on accelerating the translation of discoveries into medicines.<\/p>\n<p>\n        <strong>Presentation Details: <\/strong><br \/>\n        <br \/>\n        <u>H.C. Wainwright Annual Global Investment Conference<br \/><\/u>\n      <\/p>\n<p>Dates: September 11-13, 2023<br \/>Presentation Day\/Time: September 13 at 4:00 pm<br \/>Location: Kennedy II, Lotte New York Palace, New York<br \/>Live webcast will be available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M7uOaBAsBlggmGFa4r0Pqk49wPVAnrdqFv8AoTbIoUMuVei6I4Cqx0KRFafCIGkrRoMYKKdj5ZtCmYq7v3m9Y01SYzXIlq3Y0GXClsip77p6c7hWLF-DgMNPQ2Y7f9odgprHFwJTbUZb5_afTdovdQ==\" rel=\"nofollow noopener\" target=\"_blank\"><em>events and presentations<\/em><\/a> section of Cognition\u2019s IR site during the event<\/p>\n<p>\n        <u>Longwood Healthcare Leaders Fall Conference<\/u><br \/>\n        \n      <\/p>\n<p>Dates: September 18-19, 2023<br \/>Presentation Day\/Time: September 19 at 4:10pm<br \/>Location: Harvard Medical School, Boston<\/p>\n<p>\n        <u>Cantor Fitzgerald Global Healthcare Conference<\/u><br \/>\n        \n      <\/p>\n<p>Dates: September 26-28, 2023<br \/>Presentation Day\/Time: September 26 at 9:20 am<br \/>Location: Intercontinental Barclay Hotel, New York<br \/>Live webcast will be available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M7uOaBAsBlggmGFa4r0Pqk49wPVAnrdqFv8AoTbIoUOedk437xRCOW-mEIzBbsz3VpDziNzKSj2K9Vfm6k3lfmaHcRdtuCdSGS-zReOLCb6sCIiUXMP7jlmBaFmc8e1YOauYzlzMI4rkSfbLe_XYuQ==\" rel=\"nofollow noopener\" target=\"_blank\"><em>events and presentations<\/em><\/a> section of Cognition\u2019s IR site during the event<\/p>\n<p>\n        <strong>About Cognition Therapeutics:<\/strong><br \/>\n        <br \/>Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XVgfwL1gE2vpuzgYF0e1LsjIrS-0hi6_c_WcugETorn-dxZiJNZwVoxfzHb-0rRsNiNHJZk_c3JqQo3YPtWT1oGhFnRGhUGS1Bw95OKQn9pqef6Jj1pq8ERJlHqKETzO2JL4qW43HsQl4a_t_6GkL24xlCpc7bRvinH8hrEY0WtVr_nYa28Z3KeJe9RhF8i1hfUENHNk_Hd-JqdBCL97btGEf58oizpYgcUUP1MQlrq2IPOanzPZtLjzTADNZEke\" rel=\"nofollow noopener\" target=\"_blank\">clinical programs<\/a>\u00a0in Alzheimer\u2019s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of \u03c3-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the \u03c3-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_9e_2AERdzM4xQC5BDh41XNBdqyDAmgOc5cQ0E08mpHUcmg0J3C6nnSXJjKOFtMhrsBbTUtuMYzBTl1IZDi2M6C8MzyA9_Cnh-z8SwE7NOD91uow1AyjSZKWiZLGqH-CWzbJwMdlQ17_CojLg-zlLOt88huGM31fd5_DWB3CZxqVgAr3kt4iJKEI57Y3g22Arkkgq-AsLrKjuRT09pDXYeaCl7Wv_mLrIj9FwftUAA5Nc5ZfqbphOzatMXC-1GgaWrrrltkIUiO3vJmkLqsDbKWtNv9chuEl5YiCKGO0J2hqVfRpoQxWvMjkNCmIghfw8iVrs7AmCfk-xX9BLILOP0CVuehh6zI08p3llKiHIpKTg-t-fa8cMqcDXqcj6TZDHVf42yIxH3jeJ9XEQCynNaRPhD6d7eG1xxhFC_rUE4o4tmaENDjLr8AUa7cJU5in\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/cogrx.com\/<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials, and cash runway,\u00a0involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d might,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201caim,\u201d \u201cseek,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cforecast,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data and pre-clinical studies being predictive of the results of clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impact of the ongoing COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the \u201cRisk Factors\u201d section of our annual and quarterly reports filed the\u00a0Securities Exchange Commission. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.<\/em>\n      <\/p>\n<p>Contact Information: <br \/>Cognition Therapeutics, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RxyRSo2YfnY-ilFVYT3k9yMWKdTyeo8TtJJI-q7xN_8mwLdZtVN-hHz4vw3YyLiYq9B7JR5RZqgzV6DgDip2bg==\" rel=\"nofollow noopener\" target=\"_blank\">info@cogrx.com<\/a><\/p>\n<p>Casey McDonald (media) <br \/>Tiberend Strategic Advisors, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sOlCHT58QVEZTal7cQdFwgqssP0UG_5_WokiUY7l5VxiUh-2igTRnnXbe5XHZYz3Mp3wFYSBS1ubk_IfZaca6-0cEuepIR1CO8m1eORIa4U=\" rel=\"nofollow noopener\" target=\"_blank\">cmcdonald@tiberend.com<\/a> \u00a0\u00a0\u00a0<\/p>\n<p>Daniel Kontoh-Boateng (investors) <br \/>Tiberend Strategic Advisors, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JesZQna4Hk5s0Wbf-NAIJ1Qu0rxLpLo7YU9W4FdW3TH3JfEm-bYm9WZjyGBZoP5ZGFmpbRXTd9dufGlIKpIdTOFqGKd65cQ8xUWlS5O9uo8=\" rel=\"nofollow noopener\" target=\"_blank\">dboateng@tiberend.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzUwNCM1NzkwMjQzIzIwODQ4NzU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NWJkNWZkNDctNzk5MS00YWU1LWI4ZDQtZWY2YjU4ZDMyYmQxLTEwOTY0NDY=\/tiny\/Cognition-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; Cognition Therapeutics, Inc.\u00a0(Nasdaq: CGTX),\u00a0a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the \u201cCompany\u201d or \u201cCognition\u201d), announced that Lisa Ricciardi, Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright Annual Global Investment Conference and participating on a panel at the Cantor Fitzgerald Global Healthcare Conference in September 2023. In addition, she will be moderating a panel on pipeline prioritization strategies at the Longwood Healthcare Leaders Fall Conference, a brainstorming forum of pharmaceutical, healthcare and investment leaders focused on accelerating the translation of discoveries into medicines. Presentation Details: H.C. Wainwright Annual Global Investment Conference Dates: September 11-13, 2023Presentation Day\/Time: September 13 at 4:00 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cognition Therapeutics Announces Participation in Upcoming September Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-780971","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cognition Therapeutics Announces Participation in Upcoming September Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cognition Therapeutics Announces Participation in Upcoming September Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; Cognition Therapeutics, Inc.\u00a0(Nasdaq: CGTX),\u00a0a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the \u201cCompany\u201d or \u201cCognition\u201d), announced that Lisa Ricciardi, Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright Annual Global Investment Conference and participating on a panel at the Cantor Fitzgerald Global Healthcare Conference in September 2023. In addition, she will be moderating a panel on pipeline prioritization strategies at the Longwood Healthcare Leaders Fall Conference, a brainstorming forum of pharmaceutical, healthcare and investment leaders focused on accelerating the translation of discoveries into medicines. Presentation Details: H.C. Wainwright Annual Global Investment Conference Dates: September 11-13, 2023Presentation Day\/Time: September 13 at 4:00 &hellip; Continue reading &quot;Cognition Therapeutics Announces Participation in Upcoming September Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-30T14:20:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzUwNCM1NzkwMjQzIzIwODQ4NzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cognition Therapeutics Announces Participation in Upcoming September Conferences\",\"datePublished\":\"2023-08-30T14:20:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/\"},\"wordCount\":905,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzUwNCM1NzkwMjQzIzIwODQ4NzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/\",\"name\":\"Cognition Therapeutics Announces Participation in Upcoming September Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzUwNCM1NzkwMjQzIzIwODQ4NzU=\",\"datePublished\":\"2023-08-30T14:20:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzUwNCM1NzkwMjQzIzIwODQ4NzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzUwNCM1NzkwMjQzIzIwODQ4NzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cognition Therapeutics Announces Participation in Upcoming September Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cognition Therapeutics Announces Participation in Upcoming September Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Cognition Therapeutics Announces Participation in Upcoming September Conferences - Market Newsdesk","og_description":"PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; Cognition Therapeutics, Inc.\u00a0(Nasdaq: CGTX),\u00a0a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the \u201cCompany\u201d or \u201cCognition\u201d), announced that Lisa Ricciardi, Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright Annual Global Investment Conference and participating on a panel at the Cantor Fitzgerald Global Healthcare Conference in September 2023. In addition, she will be moderating a panel on pipeline prioritization strategies at the Longwood Healthcare Leaders Fall Conference, a brainstorming forum of pharmaceutical, healthcare and investment leaders focused on accelerating the translation of discoveries into medicines. Presentation Details: H.C. Wainwright Annual Global Investment Conference Dates: September 11-13, 2023Presentation Day\/Time: September 13 at 4:00 &hellip; Continue reading \"Cognition Therapeutics Announces Participation in Upcoming September Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-30T14:20:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzUwNCM1NzkwMjQzIzIwODQ4NzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cognition Therapeutics Announces Participation in Upcoming September Conferences","datePublished":"2023-08-30T14:20:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/"},"wordCount":905,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzUwNCM1NzkwMjQzIzIwODQ4NzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/","name":"Cognition Therapeutics Announces Participation in Upcoming September Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzUwNCM1NzkwMjQzIzIwODQ4NzU=","datePublished":"2023-08-30T14:20:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzUwNCM1NzkwMjQzIzIwODQ4NzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzUwNCM1NzkwMjQzIzIwODQ4NzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cognition-therapeutics-announces-participation-in-upcoming-september-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cognition Therapeutics Announces Participation in Upcoming September Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=780971"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780971\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=780971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=780971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=780971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}